Ids
stringlengths 36
36
| text
stringlengths 45
2.03k
| label
int64 0
1
|
|---|---|---|
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: absolute neutrophil count > or = 1,500/microliter secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: hemoglobin > or = 9.5 grams/deciliter secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: platelets >or = 75,000/microliter secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: total bilirubin < or = 1.5 X institutional upper limit of normal secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |